BCL2 and prostate cancer: This study aimed to characterize mutations in exons 5-6 of <i>TP53</i> in oral cavity cancer (OCC), prostate cancer (PC), and breast cancer (BC) in a Senegalese population, and to assess their structural effects, functional consequences, and impact on protein-protein interactions with BCL-2.